In March 2022, AmoyDx received approval for the company’s PD-L1 Expression Detection Kit (IHC), which leverages the CST PD-L1 antibody validated for immunohistochemistry (IHC) and is used to ...

Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services ... highly validated antibody products from initial discovery ...

This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody ...

Rising Investments in Biomedical Research: Global academic and commercial research institutions are increasingly focused on molecular biology, immunology, and cell signaling, creating robust demand ...

--(BUSINESS WIRE)--Cell Signaling Technology (CST), a leading provider of antibodies, kits and services ... second year in a row with the award for “Antibody Company of the Year.” ...

Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, today announced a comprehensive collaboration with Cell Signaling ...

"Our partnership with Bio-Rad in the past has enabled CST to combine our antibody expertise with Bio-Rad's strength in multiplexed assay technologies," said Christopher Bunker, CST's Director of ...

This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET, empowering researchers to develop antibody ...